Fig. 2From: Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trialPFS (a) and OS (b) in nivolumab vs. placebo group according to each potential predictive biomarkerBack to article page